NCT02156674View on ClinicalTrials.gov

Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

NATerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

January 26, 2016

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions

Maroteaux-Lamy Syndrome

Interventions

DRUG

Naglazyme®

1 mg per kg of body weight administered once weekly as an intravenous infusion

Trial Locations (1)

55455

University of Minnesota Medical Center, Fairview, Minneapolis

Sponsors

Collaborators (1)

BioMarin Pharmaceutical

All Listed Sponsors

collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02156674 - Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome | Biotech Hunter | Biotech Hunter